• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Irving D. Kaplan, MD


  • Brenner MJ, Kaplan ID.Is There Any Benefit From Hypofractionation in External-Beam Irradiation for Prostate Cancer?.J Clin Oncol. 2014 Apr 28.
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA.Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.J Oncol Pract. 2014 Mar 1;10(2):107-12.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Models of care and NCCN guideline adherence in very-low-risk prostate cancer.J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.
  • Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, .Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience.Int J Radiat Oncol Biol Phys. 2013 Apr 2.
  • Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I.Accuracy of Endorectal Magnetic Resonance/Transrectal Ultrasound Fusion for Detection of Prostate Cancer During Brachytherapy.Urology. 2013 Mar 9.
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.J Clin Oncol. 2012 Sep 1;30(25):3071-6.
  • Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID.Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153.Cancer. 2010 Sep 30.
  • Sanda MG,Kaplan ID.A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment.JAMA. 2009 May 27;301(20):2141-51.
  • Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R.Metastatic tumours to the oral cavity - Pathogenesis and analysis of 673 cases.Oral Oncol. 2008 Aug;44(8):743-52. Review.
  • Petit JH, Gluck C, Kiger WS 3rd, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I.Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.Urol Oncol.;26(4):372-7.
  • Lu XQ, Shanmugham LN, Mahadevan A, Nedea E, Stevenson MA, Kaplan I, Wong ET, La Rosa S, Wang F, Berman SM.Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy.Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):281-9.
  • Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT.Quality of life and satisfaction with outcome among prostate-cancer survivors.N Engl J Med. 2008 Mar 20;358(12):1250-61.
  • Petit JH, Gluck C, Kiger WS 3rd, Laury Henry D, Karasiewicz C, Talcott JA, Berg S, Holupka EJ, Kaplan ID.Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.Brachytherapy. 2007 Oct-Dec;6(4):267-71.
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.Cancer. 2007 Nov 15;110(10):2210-7.
  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A.Prostate cancer in a transgender woman 41 years after initiation of feminization.JAMA. 2006 Nov 15;296(19):2316-7.
  • Kaplan ID, Meskell P, Oldenburg NE, Saltzman B, Kearney GP, Holupka EJ.Real-time computed tomography dosimetry during ultrasound-guided brachytherapy for prostate cancer.Brachytherapy. 2006 Jul-Sep;5(3):147-51.
  • Hurwitz MD, Kaplan ID, Hansen JL, Prokopios-Davos S, Topulos GP, Wishnow K, Manola J, Bornstein BA, Hynynen K.Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile.Int J Hyperthermia. 2005 Nov;21(7):649-56.
  • Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV.Time course and predictors of symptoms after primary prostate cancer therapy.J Clin Oncol. 2003 Nov 1;21(21):3979-86.
  • Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.Urology. 2003 Jul;62(1):99-104.
  • Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW.Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.Am J Clin Oncol. 2003 Jun;26(3):312-6.
  • Kaplan ID, Holupka EJ, Meskell P, Soon SJ, Saltzman B, Church P, Kearney GP.Intraoperative treatment planning for radioactive seed implant therapy for prostate cancer.Urology. 2000 Sep 1;56(3):492-5.
  • McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR.Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.Cancer Res. 1999 Sep 1;59(17):4291-6.
  • Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW.Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study.J Clin Oncol. 1998 Jan;16(1):275-83.
  • D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN.Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):335-40.
  • D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN.Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1053-8.
  • Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, Wishnow K, Kaplan I, Stork PJ, Loda M.Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.Lab Invest. 1997 Jan;76(1):37-51.
  • Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA.Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study.J Clin Oncol. 1997 Jan;15(1):223-9.
  • Holupka EJ, Kaplan ID, Burdette EC, Svensson GK.Ultrasound image fusion for external beam radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):975-84.
  • Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W.Detection of circulating tumor cells in men with localized prostate cancer.J Clin Oncol. 1994 Dec;12(12):2634-9.
  • Kaplan ID, Cox RS, Bagshaw MA.Radiotherapy for prostatic cancer: patient selection and the impact of local control.Urology. 1994 May;43(5):634-9.
  • Coleman CN, Kaplan ID.Prostate cancer. Technology versus biology.Cancer. 1993 Jul 15;72(2):305-9.
  • Bagshaw MA, Kaplan ID, Cox RC.Prostate cancer. Radiation therapy for localized disease.Cancer. 1993 Feb 1;71(3 Suppl):939-52.